Lynparza Approved To Treat High-Risk, Early-Stage, HER2-, BRCA+

moderators

Lynparza Approved To Treat High-Risk, Early-Stage, HER2-Negative Breast Cancer With BRCA Mutation
Mar 13, 2022
The FDA approved Lynparza to treat early-stage, HER2-negative breast cancer with a BRCA1 or BRCA2 mutation and a high risk of recurrence, which also has been previously treated with chemotherapy — either before or after surgery. Read more...